The ANSTO Nuclear Medicine (ANM) facility has received a regulatory licence that will allow it to move to full production of molybdenum-99 (Mo-99), the Australian nuclear science and technology organisation announced today. Limited manufacturing of the isotope began in April after the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) amended a licence issued in April 2018 authorising ANSTO to operate the facility for the purpose of 'hot' commissioning only. The regulator's CEO, Carl-Magnus Larsson, on 24 May further amended the licence to enable routine production of Mo-99 to commence.

To read more please visit:

https://world-nuclear-news.org/Articles/Australian-isotope-facility-to-begin-full-scale-op

Source: World Nuclear News